Medical Developments International Limited (MVP) AI Stock Analysis

• Market Cap: AU$69.85M
• Dividend Yield: N/A
• Average Volume (3M): 169.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: 13.61%
• EPS Growth: -55.12%
• Country: AU
• Employees: 68
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 112,658,325
• 10 Day Avg. Volume: 88,356
• 30 Day Avg. Volume: 169,802
• PEG Ratio: -0.07
• Price to Book (P/B): 0.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.80
• Price Target Upside: 29.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: ―

Medical Developments International Limited has a low overall stock score due to significant financial challenges. Persistent losses and negative profit margins highlight operational inefficiencies. The technical analysis provides mixed indicators, with some short-term upward momentum but potential overbought conditions. Valuation remains a concern with a negative P/E ratio and no dividend yield, reflecting profitability and risk issues.

Medical Developments International Limited Business Overview & Revenue Model

Company Description

Medical Developments International Limited (MVP) is a leading healthcare company specializing in innovative medical solutions across various sectors, including pain management, respiratory products, and veterinary equipment. The company is well-known for its flagship product, Penthrox, a fast-acting inhaled analgesic used for pain relief in emergency situations. Additionally, MVP develops and manufactures a range of medical devices and equipment aimed at improving patient care and outcomes.

How the Company Makes Money

MVP generates revenue primarily through the sale of its medical products, particularly Penthrox, which has a strong presence in multiple international markets. The company also earns income from its respiratory and veterinary product lines, which include asthma devices and veterinary anaesthetic equipment. Key revenue streams involve direct product sales to healthcare providers, hospitals, and distributors. Significant partnerships with international pharmaceutical companies and distributors help expand its market reach and sales potential. Furthermore, MVP invests in research and development to enhance its product offerings and maintain its competitive edge in the medical industry.

Medical Developments International Limited Financial Statement Overview

Summary

Medical Developments International Limited faces significant financial challenges across all financial statements. The income statement reveals persistent losses and negative profit margins, indicating operational inefficiencies. While the balance sheet shows low leverage, the negative return on equity reflects profitability struggles. The cash flow statement highlights liquidity issues with negative operating and free cash flows. The company must address cost management and improve operational efficiency to achieve financial stability.

Income Statement

The company's income statement reveals a concerning trend, with declining revenue and significant losses in recent years. The gross profit margin has been negative in past years, indicating cost management issues. Despite a slight revenue increase in 2024, net profit margins remain deeply negative. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Overall, the income statement reflects financial instability and a challenging path to profitability.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, reflecting relatively low leverage, which provides some stability. However, the return on equity is negative due to consistent net losses. The equity ratio is reasonably strong, suggesting a solid base of equity relative to assets, but the trend of declining equity over recent years is concerning. Overall, the balance sheet shows some strengths in terms of low debt levels, but the negative equity returns highlight profitability issues.

Cash Flow

The cash flow statement indicates significant challenges, with negative operating and free cash flows consistently. The operating cash flow to net income ratio suggests poor cash conversion, and the free cash flow to net income ratio is also negative, highlighting cash flow inadequacies. While there was an improvement in free cash flow in 2024, the overall cash flow situation remains weak, pointing to liquidity concerns and reliance on external financing.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
38.05M	33.15M	32.34M	21.94M	25.27M	22.54M
	Gross Profit
17.67M	24.37M	-2.52M	-3.06M	16.67M	13.74M
	EBIT
-1.17M	-16.87M	-20.27M	-15.70M	-5.24M	1.87M
	EBITDA
-15.53M	-29.45M	-4.28M	-12.86M	-11.11M	3.03M
	Net Income Common Stockholders
-29.74M	-40.99M	-5.61M	-12.41M	-12.56M	379.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.13M	9.73M	24.66M	20.40M	36.28M	15.54M
	Total Assets
19.10M	59.16M	109.49M	101.36M	100.17M	94.85M
	Total Debt
0.00	2.29M	2.56M	2.81M	3.05M	3.36M
	Net Debt
-2.13M	-7.45M	-22.10M	-17.59M	-33.23M	-12.19M
	Total Liabilities
1.52M	13.43M	28.17M	44.06M	31.87M	51.51M
	Stockholders Equity
16.64M	45.73M	81.31M	57.30M	68.30M	43.34M
Cash Flow		Free Cash Flow
-6.79M	-13.95M	-24.16M	-15.94M	-15.37M	-8.30M
	Operating Cash Flow
-5.08M	-10.78M	-16.50M	-10.72M	-8.81M	601.00K
	Investing Cash Flow
-2.06M	-3.17M	-7.67M	-5.21M	-6.56M	-8.90M
	Financing Cash Flow
8.69M	-807.00K	28.06M	142.00K	36.12M	-1.97M

Medical Developments International Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.62
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVP, the sentiment is Neutral. The current price of 0.62 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.56, and above the 200-day MA of 0.52, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 49.16 is Neutral, neither overbought nor oversold. The STOCH value of 29.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:MVP.

Medical Developments International Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	79 Outperform	AU$56.78B	27.93	25.23%	0.85%	10.54%	38.69%
COH	73 Outperform	$17.56B	47.45	20.61%	1.61%	6.35%	5.97%
SHL	72 Outperform	AU$12.68B	23.17	6.86%	4.05%	10.15%	6.20%
CSL	69 Neutral	$117.14B	28.12	15.38%	1.85%	8.00%	9.09%
RHC	66 Neutral	$8.65B	1,057.58	0.52%	2.23%	7.25%	-99.04%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
MVP	44 Neutral	AU$69.85M	―	-45.40%	―	13.61%	-55.12%

Medical Developments International Limited Corporate Events

Medical Developments International Issues New Performance Rights

Medical Developments International Limited announced the issuance of 2,687,635 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s strategy to incentivize its workforce and align their interests with corporate performance, potentially impacting its operational efficiency and market positioning.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Appoints New Director to Drive Strategic Growth

Medical Developments International Limited announced the resignation of Richard Betts and the appointment of Paul Townsend to its Board, effective 30 May 2025. Paul Townsend, a seasoned finance leader with extensive experience across multiple sectors, will assume the role of Chair of the Audit & Risk Committee. His background in driving business outcomes and leading major organizational changes is expected to support MVP’s strategic growth objectives. The company anticipates that Townsend’s expertise will aid in unlocking its full potential and achieving long-term global growth.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Reports Strong Q3 FY25 Performance

Medical Developments International Limited reported strong financial performance for Q3 FY25, with a $1.7 million operating cash flow and a cash balance of $19.1 million. The company saw increased demand for Penthrox in both the Australian hospital segment and European markets, signing a new distribution agreement with Ethypharm in France. Despite expected lower earnings in the second half of FY25 due to foreign exchange rates, the company anticipates improved full-year EBIT driven by higher Penthrox prices and operational efficiencies.

Medical Developments International Appoints New Director

Medical Developments International Limited has announced the appointment of Mark Fladrich as a director effective April 1, 2025. The announcement, made under listing rule 3.19A.1, indicates that there are currently no relevant interests in securities or contracts associated with the new director, which suggests a straightforward transition without immediate financial implications for the company.